MiMedx Group (MDXG) to Release Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is scheduled to be announcing its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03. The business had revenue of $84.71 million during the quarter, compared to analysts’ expectations of $79.36 million. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

MDXG opened at $7.62 on Tuesday. MiMedx Group has a 12-month low of $5.57 and a 12-month high of $9.27. The firm has a market capitalization of $1.12 billion, a P/E ratio of 17.32 and a beta of 1.99. The stock’s 50 day moving average price is $7.15 and its two-hundred day moving average price is $7.46. The company has a quick ratio of 2.71, a current ratio of 3.29 and a debt-to-equity ratio of 0.12.

Analysts Set New Price Targets

MDXG has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Wednesday, May 1st. Cantor Fitzgerald initiated coverage on shares of MiMedx Group in a report on Tuesday, July 2nd. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 11th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.